NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 04/21/2022 19:53
Last Report Issued 04/04/2022 06:14

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 9293SP-POS
Patient ID 9293SP-POS
Chain 22000239
DOB Not Given
Sex Not Given
Workorder 22000239

Received 01/24/2022

Lab ID 22000239-001
Matrix Serum or Plasma
Patient Name 9293SP-POS
Patient ID 9293SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
9293SP Methylenedioxymethamphetamine and Metabolite Screen, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/Time of Flight-Mass Spectrometry (LC/TOF-MS)				
MDA	See Comment	ng/mL	10	
Synonym(s): 3,4-Methylenedioxyamphetamine; Adam; MDMA Metabolite				
Comment: Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).				
MDA is a metabolite of MDMA and methylenedioxyethylamphetamine (MDEA) and is abused for its central nervous system stimulant and hallucinogenic properties. The peak concentration of the MDA metabolite following a 110 mg dose of MDMA was reported as 28 ng/mL at 4 hours.				
MDMA	See Comment	ng/mL	10	
Synonym(s): 3,4-Methylenedioxymethamphetamine; Ecstasy				
Comment: Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).				
Following a single 50 mg oral dose, the mean peak plasma concentration was 110 ng/mL at 2 hours.				

Results for sample 22000239-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Lab ID 22000239-001
Matrix Serum or Plasma
Patient Name 9293SP-POS
Patient ID 9293SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

5696SP Methylenedioxymethamphetamine and Metabolite Confirmation, Serum/Plasma

Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)

MDMA	50	ng/mL	5.0

Synonym(s): 3,4-Methylenedioxymethamphetamine; Ecstasy

Following a single 50 mg oral dose, the mean peak plasma concentration was 110 ng/mL at 2 hours.

MDA	50	ng/mL	5.0

Synonym(s): Adam; 3,4-Methylenedioxyamphetamine; MDMA Metabolite

MDA is a metabolite of MDMA and methylenedioxyethylamphetamine (MDEA) and is abused for its central nervous system stimulant and hallucinogenic properties.
The peak concentration of the MDA metabolite following a 110 mg dose of MDMA was reported as 28 ng/mL at 4 hours.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.